This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
5u6i
From Proteopedia
| Line 1: | Line 1: | ||
==Discovery of MLi-2, an Orally Available and Selective LRRK2 Inhibitor that Reduces Brain Kinase Activity== | ==Discovery of MLi-2, an Orally Available and Selective LRRK2 Inhibitor that Reduces Brain Kinase Activity== | ||
| - | <StructureSection load='5u6i' size='340' side='right' caption='[[5u6i]], [[Resolution|resolution]] 1.69Å' scene=''> | + | <StructureSection load='5u6i' size='340' side='right'caption='[[5u6i]], [[Resolution|resolution]] 1.69Å' scene=''> |
== Structural highlights == | == Structural highlights == | ||
| - | <table><tr><td colspan='2'>[[5u6i]] is a 1 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5U6I OCA]. For a <b>guided tour on the structure components</b> use [http:// | + | <table><tr><td colspan='2'>[[5u6i]] is a 1 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5U6I OCA]. For a <b>guided tour on the structure components</b> use [http://proteopedia.org/fgij/fg.htm?mol=5U6I FirstGlance]. <br> |
| - | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=81Y:3-[2-(MORPHOLIN-4-YL)PYRIDIN-4-YL]-5-[(PROPAN-2-YL)OXY]-1H-INDAZOLE'>81Y</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr> | + | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=81Y:3-[2-(MORPHOLIN-4-YL)PYRIDIN-4-YL]-5-[(PROPAN-2-YL)OXY]-1H-INDAZOLE'>81Y</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr> |
<tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Mitogen-activated_protein_kinase Mitogen-activated protein kinase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.11.24 2.7.11.24] </span></td></tr> | <tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Mitogen-activated_protein_kinase Mitogen-activated protein kinase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.11.24 2.7.11.24] </span></td></tr> | ||
| - | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http:// | + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://proteopedia.org/fgij/fg.htm?mol=5u6i FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5u6i OCA], [http://pdbe.org/5u6i PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5u6i RCSB], [http://www.ebi.ac.uk/pdbsum/5u6i PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5u6i ProSAT]</span></td></tr> |
</table> | </table> | ||
== Function == | == Function == | ||
| Line 19: | Line 19: | ||
</div> | </div> | ||
<div class="pdbe-citations 5u6i" style="background-color:#fffaf0;"></div> | <div class="pdbe-citations 5u6i" style="background-color:#fffaf0;"></div> | ||
| + | |||
| + | ==See Also== | ||
| + | *[[Mitogen-activated protein kinase 3D structures|Mitogen-activated protein kinase 3D structures]] | ||
== References == | == References == | ||
<references/> | <references/> | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
| + | [[Category: Large Structures]] | ||
[[Category: Mitogen-activated protein kinase]] | [[Category: Mitogen-activated protein kinase]] | ||
[[Category: Agnihotri, G]] | [[Category: Agnihotri, G]] | ||
Revision as of 12:27, 23 September 2020
Discovery of MLi-2, an Orally Available and Selective LRRK2 Inhibitor that Reduces Brain Kinase Activity
| |||||||||||
Categories: Large Structures | Mitogen-activated protein kinase | Agnihotri, G | Baptista, M | Basu, K | Chang, R K | Columbus, J | Dai, X | DeMong, D E | Drolet, R E | Embrey, M W | Fell, M J | Greshock, T J | Harris, J | Hruza, A | Kennedy, M E | Kern, J T | Li, W | Lin, S | Lin, Y | Liu, H | McCauley, J A | Mei, H | Miller, M W | Mirescu, C | Morrow, J A | Nargund, R | Parker, E M | Poirier, M | Sanders, J M | Scott, J D | Stamford, A W | Tiscia, H E | Xiao, L | Yin, Z | Zhou, X | Kinase inhibitor | Kinase selectivity | Lrrk2 | Map kinase | Mli-2 | Parkinson's disease | Serine/ threonine-protein kinase | Transferase | Transferase-transferase inhibitor complex
